| Tag | Content |
|---|
EnhancerAtlas ID | HS133-02631 |
Organism | Homo sapiens |
Tissue/cell | melanoma |
Coordinate | chr1:159023740-159024610 |
Target genes | |
TF binding sites/motifs | | TF | JASPAR ID | Coordinate | Motif Sequence | Strand | -Log10(p-value) |
| Sox3 | MA0514.1 | chr1:159024143-159024153 | AAAACAAAGG | - | 6.02 |
|
| | Number of super-enhancer constituents: 6 | ID | Coordinate | Tissue/cell |
| SE_09429 | chr1:159020008-159026582 | CD14 | | SE_10770 | chr1:159023635-159026364 | CD19_Primary | | SE_11012 | chr1:158996533-159048941 | CD20 | | SE_18632 | chr1:159010634-159026142 | CD4p_CD25-_Il17-_PMAstim_Th | | SE_19676 | chr1:159023945-159024790 | CD4p_CD25-_Il17p_PMAstim_Th17 | | SE_62721 | chr1:159022449-159048523 | Tonsil |
|
| | Diseases: AD,Huntington,Obesity,Parkinson,Prostate cancer,Schizophrenia and Sleep disorder | | Number of disease enhancers: 1 | Chromosome | Start | End |
|
| | Number: 1 | ID | Chromosome | Start | End |
| GH01I159054 | chr1 | 159023804 | 159025995 |
|
Enhancer Sequence | TAAGAAAGAA TTGGTTGCTT TTACCACAAT GTGGAGATAA TTTAATAAGA ATTTGGGTTT 60
GGTTAAGGCA CATTTGTTTC AACTAGCTGG TTCTGTGACT TTCTAGTTGA CTAAAGACTT 120
ACACTAGGAA TCTCAGGTTC ATCATTTGTG AAATGGGAGA AATACTGTCT ACCATAGAGG 180
GTCATCAACT TAGCTCACAG CAGCCCTGAA TTACCAAGAA TGCATCTGAG CAAATCAGAT 240
CACAAAGGTA CCTGCCTTTA GTGAGATACA TACACTGGTT TACATCAGAC AGAGGTAGCT 300
GGGTCTACAT AACAAAGTCC ATGCTTTTTG CCACACTGAC CCATACATTC ATGTGGGATT 360
CTTGGAACAC TAACAAAGGC TAATATTAGA AGGCAAATAG TTCAAAACAA AGGCTGACAT 420
ATTCAGGCAC ACACATGCTC TCAGATTGCT CCAGTTCTCA GGACCAGCAG TCAAACATTT 480
CAAACCTTCT TTGATAGCAA TTGCACCAGG AATACCTTTT GTACTCTCCC CCTTCCTTCT 540
GCCCAATGAA AACCCTCTCC TCAACTCTTG TCATTGGGTG CACCAGCTCC TTTCTCTCTC 600
CTGTTGTTCC CTGACATCTC CTGCTCTTTC ACTTGCACTC ATGCTGAGTA GGAGTGAATA 660
TCTCATTTCA CGGTCCAAAT TAAACAGAGA GGCATGACTC AAAGGTCAAG AATTTATTAA 720
GGGAGATAGA TGAGAGCGAG AAAAGAATCA TTTAGAAAGG AATAGGGGAA GAGATATGGT 780
GCAGGGGGAG GAGATACAGT GTGATTGAAG GGAGAAATGT AGGATCATCA GCATCTCAAC 840
TGGTCTGTCT TTATCTCTTT CTCCTTCAAG 870
|
